Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: ProgModule: A novel computational framework to identify mutation driver modules for predicting cancer prognosis and immunotherapy response

Fig. 6

ProgModule can be used to predict the clinical outcomes of patients receiving immunotherapy. (A) The enriched KEGG pathways of genes involved in all candidate modules in the Van Allen cohort. (B) Circle plot depicting the impact on melanoma overall survival of five candidate module mutations. (C) Kaplan-Meier survival analysis of OS comparing the High-risk and Low-risk groups from the Van Allen cohort. (D) Comparison of ORR between the High-risk and Low-risk groups in the Van Allen cohort. (E) Kaplan-Meier survival analysis of OS comparing the High-risk and Low-risk groups from the Miao cohort. (F) Comparison of ORR between the High-risk and Low-risk groups in the Miao cohort. (G) Compared the performance of our method with other published immunotherapy biomarkers based on C-index and MCC. (H) Heatmap depicting the Z score of seven candidate genes in the top 10% of ranked genes across different CRISPR datasets

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us